Thyroid Function And 3, 3'-Diiodothyronine Sulfate Cross-Reactive Substance (Compound W) in Maternal Hyperthyroidism With Antithyroid Treatment |
| |
| Institution: | 1. Departments of Physiology,;2. Medicine,;3. Obstetrics and Gynecology, and;4. Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, and;5. Nuclear Medicine-Medical Services, Department of Veterans Affairs Medical Center, Long Beach, California.;1. Biological Process of Aging, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo 173-0015, Japan;2. Animal Facility, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo 173-0015, Japan;3. Department of Aging Control Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo 113-0033, Japan;1. Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;2. Department of Psychiatry, Kawamuro Memorial Hospital, Niigata, Japan;3. University of Tokyo Institute for Diversity & Adaptation of Human Mind (UTIDAHM), Tokyo, Japan;4. Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, The University of Tokyo, Tokyo, Japan;5. Department of Rehabilitation, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;6. Department of Youth Mental Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan |
| |
| Abstract: | ObjectiveTo test whether the serial measurement of maternal levels of compound W, a 3, 3′-diiodothyronine sulfate cross-reactive substance, can serve as a potential indicator of fetal thyroid function in pregnant women receiving antithyroid medication.MethodsCompound W was measured repeatedly in serum of pregnant women with hyperthyroidism treated with antithyroid medication. Free thyroxine levels of mothers and serum thyroid-stimulating hormone levels of 1-day-old neonates were analyzed by local clinical or state laboratories.ResultsUse of minimal antithyroid medication impaired the progressive increase of compound W seen in euthyroid mothers during pregnancy. At term, depressed compound W levels in maternal serum were found in 7 of 22 pregnancies; in 1 case, maternal compound W was suppressed and newborn thyroid-stimulating hormone was elevated. Seven mothers with treated hyperthyroidism failed to show an increase in serum levels of compound W after midterm.ConclusionNormal progression of maternal serum compound W may be an index of normal fetal thyroid development in mothers with hyperthyroidism treated with necessary antithyroid medication. (Endocr Pract. 2011;17:170-176) |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
